Robert A. Figlin Appointed Leadership Role at Cedars-Sinai Medical Center

Robert A. Figlin, MD has been appointed the deputy director of the Integrated Oncology Service Line at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center.

Robert A. Figlin, MD

Robert A. Figlin, MD has been appointed the deputy director of the Integrated Oncology Service Line at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center. His role will be to integrate research and clinical strategies across the organization.

Figlin previously served as the director of the Hematology Oncology Division at the institute.

In his new role, Figlin will work with clinicians and investigators to unify the health system's approach to treating cancer. This integration means patients will get the same level of quality services whether they're treated at Cedars-Sinai's main campus or at one of its affiliates, including Tower Hematology Oncology and The Angeles Clinic.

"Dr. Figlin was tailor-made to do this," said Steven Piantadosi, MD, PhD, director of the Samuel Oschin Comprehensive Cancer Institute and professor of Medicine at Cedars-Sinai. "He's an experienced leader who knows cancer care in the Cedars-Sinai system, throughout Los Angeles and beyond."

Figlin, a kidney cancer specialist, will also continue to work developing clinical trials, translating research findings from the laboratory to the clinical setting, and leading initiatives such as Cedars-Sinai's effort to contain the high cost of cancer drugs.

He first joined Cedars-Sinai six years ago, as the Steven Spielberg Family Chair in Hematology Oncology. Since his arrival, he has established the Experimental Therapeutics Program and successfully recruited clinical and research faculty in critical specialty areas such as breast cancer, bone marrow transplant, gastrointestinal oncology, genitourinary oncology, survivorship and cancer biology, among many other achievements.

His new position, he says, will provide additional opportunities to enhance the lives of cancer patients, while advancing significant research goals.